Main Article Content
Tamoxifen is the most commonly used drug in the treatment of breast cancer via blocking the estrogen receptor pathway. However, the use of Tamoxifen is limited by intrinsic and acquired resistance, which may be associated with the de-regulation of the kinase protein expression or an increase in multiple drug resistance (MDR) expression. Two breast cancer cell lines, wild type MCF7 WT (sensitive, i.e., ER+) and MDA-MB-231 (resistant, i.e., ER-), were used. Expression of P-glycoprotein (Pgp) was measured, the cells were treated with 4- hydroxy tamoxifen in the presence or absence of anti-stem cell factor, apoptosis protein (Annexin V) was measured and Influx/efflux rates were monitored by using Technetium99m methoxyisobutylisonitrile (99m Tc-Sestamibi-MIBI) at different time intervals. Results showed positive expression of AnnexinV in MDA-MB-231 and MCF7/WT, and the effect of blocking of the stem cell factor showed an increase in the drug accumulation within the MDA-MB-231 cell line. In conclusion, this study showed that the anti-stem cell factor enhances the effectiveness of antihormonal therapies determined by 99m Tc-MIBI. These findings may have implications for the use of anti-stem cell factor with anti-hormonal therapy in ER-negative breast cancer in order to overcome drug resistance and improve the outcome.
How to cite this article: Arif, K.B., Hussain, I., Rea, C. and El-Sheemy, M. (2019). Stem Cell Factor Antibody: Effective Manipulation of Antihormonal Therapy in Resistant Human Breast Cancer In Vitro. International Journal of Drug Delivery Technology, 9(4): 608-612.
Source of support: Nil.
Conflict of interest: None.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.